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Abstract
Background: Bartter and Gitelman syndromes are autosomal recessive disorders of renal tubular salt handling. Due to their
rarity, limited long-term data are available to inform prognosis and management.
Methods: Long-term longitudinal data were analysed for 45 children with pathogenic variants in SLC12A1 (n ¼ 8), KCNJ1
(n ¼ 8), CLCNKB (n ¼ 17), BSND (n ¼ 2) and SLC12A3 (n ¼ 10) seen at a single centre between 1984 and 2014. Median follow-up
was 8.9 [interquartile range (IQR) 0.7–18.1] years.
Results: Polyhydramnios and prematurity were seen in children with SLC12A1 and KCNJ1 mutations. Patients with CLCNKB
mutations had the lowest serum potassium and serum magnesium and the highest serum bicarbonate levels. Fractional
excretion of chloride was >0.5% in all patients prior to supplementation. Nephrocalcinosis at presentation was present in
the majority of patients with SLC12A1 and KCNJ1 mutations, while it was only present in one patient with CLCNKB and not
in SLC12A3 or BSND mutations. Growth was impaired, but within the normal range (median height standard deviation score
1.2 at the last follow-up). Impaired estimated glomerular filtration rate (eGFR <90 mL/min/1.73 m2) at the last follow-up
was seen predominantly with SLC12A1 [71 mL/min/1.73 m2 (IQR 46–74)] and KCNJ1 [62 mL/min/1.73 m2 (IQR 48–72)]
mutations. Pathological albuminuria was detected in 31/45 children.
Conclusions: Patients with Bartter and Gitelman syndromes had a satisfactory prognosis during childhood. However,
decreased eGFR and pathologic proteinuria was evident in a large number of these patients, highlighting the need to
monitor glomerular as well as tubular function. Electrolyte abnormalities were most severe in CLCNKB mutations both at
presentation and during follow-up. Fractional excretion of chloride prior to supplementation is a useful screening
investigation in children with hypokalaemic alkalosis to establish renal salt wasting.
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Introduction
Bartter syndrome (BS) and Gitelman syndrome (GS) are rare
autosomal recessive tubulopathies with a prevalence of 1 in
100 000 and 25 in 100 000, respectively [1]. BS occurs as a result
of mutations in genes coding for proteins mainly responsible for
salt and water reabsorption in the thick ascending loop of Henle
(TAL), while dysfunction of the sodium chloride co-transporter in
the distal convoluted tubule (DCT) results in GS. BS can be further
subdivided based on the underlying genetics (Table 1) [2–6].
Two broad phenotypes exist in BS: antenatal BS, due to
mutations in SLC12A1, KCNJ1, BSND (with sensorineural hearing
loss) and in some cases of CLCNKB; and classic BS, typically
associated with mutations in CLCNKB. Recently a transient
antenatal BS was described in boys with mutations in MAGED2
[7]. Biochemical hallmarks of BS and GS include hyperaldoster-
onism with hypokalaemic, hypochloraemic metabolic alkalosis.
Some specific biochemical abnormalities can give clues as to
the underlying genotype, summarized in Table 1. For example,
patients with KCNJ1 mutations can present with transient
hyperkalaemia followed by the more typical hypokalaemia;
increased urinary calcium excretion and nephrocalcinosis are
present in SLC12A1 and KCNJ1 mutations, whereas patients with
SLC12A3 mutations have hypocalciuria; and patients with CLCNKB
and SLC12A3 mutations typically develop hypomagnesaemia.
As with most rare diseases, there is little data available
about the long-term disease course to inform management and
prognosis.
In this study we describe the presenting features and long-
term outcomes of 45 patients with BS and GS.
Materials and methods
Demographic data
Biochemical and clinical data were analysed for 45 children pre-
senting to Great Ormond Street Hospital (GOSH) between 1984
and 2014. Results were collected at presentation and throughout
follow-up, summarized in Table 2. Estimated glomerular filtra-
tion rate (eGFR) was calculated using the modified Schwartz
formula, with a k-value of 33 [8]. The median follow-up was 8.9
[interquartile range (IQR) 0.5–18.1] years.
Statistical analysis
Data analysis was performed using SPSS (IBM, Armonk, NY, USA).
Patients were analysed according to the underlying disease
gene—SLC12A1, KCNJ1, CNCKB, BSND and SLC12A3—to investigate
genotype/phenotype correlation. The Mann–Whitney U test was
used to investigate differences between individual genotypes and
Kruskal–Wallis was used to evaluate differences between multi-
ple groups; statistical significance was defined as P < 0.05.
Median values are given with IQRs throughout. Due to the
small size, the BSND group was excluded from statistical analysis.
Molecular analysis
Genotyping was performed by the North East Thames Regional
Genetics Service, located at GOSH, using a kit to assess a panel
of 37 tubular disease genes, as described previously [9].
Results
Molecular results
Mutations in disease-causing genes are summarized in Table 3.
Homozygous variants were identified in 30/45 patients and
compound heterozygous variants in the remaining 15/45
patients. Whole gene deletion was responsible for 50% of muta-
tions in CLCNKB.
Initial presentation
Biochemical and clinical features at presentation are summar-
ized in Table 2 and Figure 1.
Prenatal and perinatal history
Polyhydramnios was documented in 8/8 of SLC12A1, 7/8 KCNJ1,
7/17 CLCNKB, 1/2 BSND and 0/10 SLC12A3 cases. Gestational
age (GA) was significantly lower in SLC12A1, KCNJ1 and BSND
mutations compared with CLCNKB and SLC12A3 (P < 0.001).
Diagnosis and presentation
The diagnosis of BS or GS was made before the age of 1 year in
27/35 BS patients (8/8 SLC12A1, 8/8 KCNJ1, 9/17 CLCNKB and 2/2
BSND) compared with 1/10 GS patients. Children diagnosed
before 1 year of age presented with a history of polyhydramnios,
polyuria and hypochloraemic metabolic alkalosis. The remain-
ing patients were diagnosed during childhood with failure to
thrive (four CLCNKB), persistent muscle cramping (one CLCNKB,
one SLC12A3), fainting spells (one SLC12A3) and incidentally
noted biochemical derangement during intercurrent illness
(one CLCNKB, seven SLC12A3).
Median plasma potassium concentration at presentation
was lowest in CLCNKB mutations [2.6 mmol/L (IQR 2.1–2.9)],
Table 1. Clinical and genetic classification of BS and GS
Clinical phenotype OMIM
Genetic
subtype Gene/locus Protein Features
Antenatal BS 601678 Type I SLC12A1/15q21.1 NKCC2 Polyhydramnios, prematurity, polyuria, nephrocalci-
nosis, failure to thrive
Antenatal BS 241200 Type II KCNJ1/11q24.3 ROMK1 Polyhydramnios, prematurity, polyuria, nephrocalci-
nosis, failure to thrive, transient hyperkalaemia
Classic BS 607364 Type III CLCNKB/1p36.13 CLC-Kb Failure to thrive, hypomagnesaemia
Antenatal BS with
sensorineural deafness
602522 Type IV BSND/1p32.3 Barttin Polyhydramnios, prematurity, polyuria, nephrocalci-
nosis, failure to thrive, sensorineural deafness
GS 263800 GS SLC12A3/16q13 NCCT Hypocalciuria, hypomagnesaemia
Transient antenatal BS 300971 Type V MAGED2 MAGED2 Severe polyhydramnios, prematurity, hypercalciuria,
spontaneous resolution
OMIM: Online Mendelian Inheritance in Man.
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while two children with KCNJ1 were noted to have transient
hyperkalaemia at presentation (Figure 1).
Fractional excretions of chloride (FECl) and sodium (FENa) at
presentation were calculated in children where the data were
available (FECl in 15 children and FENa in 28 patients) and are
summarized in Table 2. FENa ranged from 0.1 to 6.4%, while
FECl >0.5% was seen in all patients with available data, prior to
commencing supplementation. In patients where both values
were available (n ¼ 15), the median FENa was 0.7% (IQR 0.3–1.2)
and FECl was 1.62% (IQR 1.2–5.5).
Normal urine calcium:creatinine (UCC) ratio varies with age,
therefore the results were normalized to an age-adjusted upper
limit of normal. This was elevated in 5/8 SLC12A1, 5/8 KCNJ1, 7/
17 CLCNKB and 2/2 BSND patients. Ultrasound scan at presenta-
tion was performed in all children to assess for nephrocalcino-
sis; this was seen in 8/8 SLC12A1, 8/8 KCNJ1, 2/17 CLCNKB, 0/2
BSND and 0/10 SLC12A3 patients.
Course of clinical and biochemical data
Growth
The median height [standard deviation score (SDS)] at presenta-
tion was 1.6 (IQR 3.88 to 0.04), this was not statistically dif-
ferent from the follow-up [1.2 (IQR 3 to 1.7)]. Subgroup
analysis of the genotypes revealed no statistical difference
between height at presentation and follow-up (SDS): SLC12A1,
P ¼ 0.35; KCNJ1, P ¼ 0.6; CLCNKB, P ¼ 0.39; SLC12A3, P ¼ 0.59.
Growth hormone treatment
Growth hormone (GH) deficiency has previously been reported in
children with BS [11]. In this cohort, GH was used in three patients
(1, 10 and 23) due to documented GH deficiency based on formal
glucagon stimulation tests. In Patient 1, it was started at the age of
8 years, when her height was 110 cm (SDS3.29). She was also
treated with gonadotropin-releasing hormone analogues to delay
puberty. Treatment was stopped at the age of 16 years, when her
height was 153 cm (SDS1.42). Patient 10 started GH at the age of
14 years, when his height was 126 cm (SDS4.37) and was stopped
at the age of 17 years, when his height was 154 cm (SDS3.02).
Patient 23 started GH at the age of 6 years when his height was
102 cm (SDS3.78). This coincided with indomethacin being dis-
continued due to a gastrointestinal bleed. His height SDS remained
essentially unchanged for the following 2 years (SDS3.88) despite
GH treatment. At the age of 8 years, indomethacin was restarted
(and GH continued) and his height SDS improved to 2.75 over the
following year. At the last follow-up (still on GH and indometha-
cin) at the age of 12 years, his height was 133 cm (SDS2.26).
Persistent hypokalaemia
Persistent hypokalaemia, defined as potassium <3.5 mmol/L on
at least two consecutive blood tests, was seen in 41 children.
Mild hypokalaemia (2.5–3.5 mmol/L) was present in 28 children
(BS 22, GS 6), moderate hypokalaemia (2.0–2.5 mmol/L) was seen
in 9 children (BS 6, GS 3) and severe hypokalaemia (<2.0 mmol/
L) was noted in 4 children (3 CLCNKB and 1 BSND).
At the last follow-up, plasma potassium was decreased
(<3.5 mmol/L) in 36 patients (BS 26/35 and GS 10/10). Plasma
bicarbonate was elevated (>28 mmol/L) in 20 patients (BS 18/35
and GS 2/10) and plasma magnesium was decreased
(<0.6 mmol/L) in 7 patients (BS 3/35 and GS 4/10) (Figure 1).
Complications
Two children with CLCNKB mutations were admitted for optimi-
zation of potassium supplementation (serum potassium
1.3 mmol/L and 1 mmol/L), one due to symptoms of hypokalae-
mic paralysis (Patient 13), which resolved following increased
potassium supplementation, and the second due to concerns
regarding compliance (Patient 15).
The median serum magnesium level at the last follow-up
was lowest in GS patients [0.62 mmol/L (IQR 0.55–0.71)].
Hypomagnesaemia was associated with both CLCNKB and
SLC12A3 mutations; while there was a trend to lower magne-
sium with increasing age, this was not statistically significant.
No arrhythmias were noted.
Table 2. Clinical and biochemical characteristics at presentation
BS GS
Parameter SLC12A1 (n ¼ 8) KCNJ1 (n ¼ 8) CLCNKB (n ¼ 17) BSND (n ¼ 2) SLC12A3 (n ¼ 10) P-value
GA, weeks 32 (27–33) 30 (28–33) 40 (38–40) 32 40 (40–40) <0.001
Polyhydramnios,
present/absent
8/0 7/1 7/10 0/2 0/10 <0.001
Sex, M/F 4/4 4/4 12/5 0/2 7/4 N.S.
Height, Z-score 1.28 (4.9 to 0.62) 2.2 (3.0 to 0.4) 2.1 (4.9 to 0.11) 0.0 (1.1 to 0.5)7 N.S.
Weight, Z-score 3.49 (4.22 to 1.00)2 2.31 (3.49 to 0.22)1 1.82 (3.49 to 0.63)6 0.52 (N/A)8 N.S.
Sodium, [133–146 mmol/L] 146 (143–148) 142 (135–148) 135 (130–140) (116–130) 139 (135–140) 0.001
Potassium [3.5–5.5 mmol/L] 3.4 (2.9–3.9) 3.8 (3.6–6.0) 2.6 (2.1–2.9) (2.1–3.0) 2.8 (2.4–3.0) <0.001
Chloride [96–106 mmol/L] 103 (98–110)1 103 (101–109) 95 (81–98)1 (59–79) 98 (96–101)1 0.001
Bicarbonate [18–28 mmol/L] 25 (25–29) 25 (23–28) 29 (26–33)1 (24–81) 30 (28–31)1 0.01
Magnesium [0.6–0.9 mmol/L] 0.97 (0.91–1.17)1 0.94 (0.73–1.07)1 0.76 (0.59–0.90)2 (0.55–0.74) 0.67 (0.58–0.83)1 0.005
FENa, % 0.36 (0.17–1.23)1 0.82 (0.37–2.51)2 0.87 (0.39–1.25)8 Not obtained 0.55 (0.30–0.95)5 N.S
FECl, % 1.6 (0.8–5.4)3 1.25 (N/A)6 3.9 (1.4–6.1)11 Not obtained 2.1 (N/A)9 N.S.
Age-adjusted calcium:creatinine
ratio, normalized to
upper limit of normal
1.17 (0.88–2.00) 1.37 (0.82–2.04) 0.61 (0.14–1.34) (1.50–1.64) 0.09 (0.05–0.21) <0.001
Nephrocalcinosis,
present/absent
8/0 8/0 2/15 0/2 0/10 <0.001
Median values given with interquartile ranges in parentheses. Reference range given in square brackets. Superscript numbers indicate the number of patients with
missing data. P-values for Kruskal–Wallis analysis comparing SLC12A1, KCNJ1, CLCNKB and SLC12A3. M: male; F: female; N.S.: Not significant.
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Medications at last follow-up
Sodium supplementation was prescribed for 14/45 patients (BS 12/
35 and GS 2/10), potassium supplementation for 38/45 patients (BS
30/35, GS 8/10) and magnesium supplementation for 12/45 patients
(BS 7/35 and GS 5/10). Prostaglandin inhibitors (ibuprofen or indo-
methacin) were prescribed in 20/45 patients (BS 20/35 and GS 0/10).
Side effects of medication
Indomethacin
Indomethacin was used in 30/35 BS and 2/10 GS patients.
Indomethacin was permanently discontinued in three children:
two developed abdominal pain (Patients 17 and 24) and one
developed excessive bruising days after commencing treatment
(Patient 23).
Indomethacin was temporarily discontinued in two other
children. One child (Patient 8) developed necrotizing enteroco-
litis at 17 days of age; indomethacin was eventually recom-
menced at 3 months due to ongoing severe polyuria. The
second child developed gastrointestinal bleeding during the
first year of life (Patient 21); indomethacin was gradually rein-
troduced. Indomethacin was substituted with ibuprofen in
four patients: two because of parental preference (Patients 9.1
and 9.2), one due to abdominal pain that settled after switch-
ing (Patient 4.1) and one who developed peptic ulcer disease
Table 3. Causative mutations identified
Gene Patient Sex Nucleotide Protein Status
SLC12A1 1 Female c.1316G>A p.(Arg439Gln) Homozygous
2 Male c.1215G>A p.?(Loss of splice site) Homozygous
3 Female c.811G>C/c.1316G>A p.(Ala271Pro/p.Arg439Gln Compound heterozygous
4.1 Female c.450_451del/c.967G>A p.(Asp150Glufs*4)/p.(Glu323Lys) Compound heterozygous
4.2 Male c.450_451del/c.967G>A p.(Asp150Glufs*4)/p.(Glu323Lys) Compound heterozygous
5 Male c. 1327G>A/c.2805dup p.(G443R)/p.(Trp936fs) Compound heterozygous
6.1 Male c.3165-?_*1þ?del p.? (exon 26 deletion) Homozygous
6.2 Female c.3165-?_*1þ?del p.? (exon 26 deletion) Homozygous
KCNJ1 7 Male c.1-?_*1þ?del p.? (exon 1 deletion) Homozygous
8 Male c.277T>G p.(Phe93Val) Homozygous
9.1 Female c.716delG p.(Gly239Glufs*14) Homozygous
9.2 Female c.716delG p.(Gly239Glufs*14) Homozygous
10 Female c.658C>T p.(Leu220Phe) Homozygous
11.1 Female c.657C>G p.(Ser219Arg) Homozygous
11.2 Male c.657C>G p.(Ser219Arg) Homozygous
12 Male c.657C>G p.(Ser219Arg) Homozygous
CLCNKB 13 Male c.(?-1)_(*1_?)del p.? (gene deletion) Homozygous
14.1 Female c.875G>T p.(Cys292Phe) Homozygous
14.2 Male c.875G>T p.(Cys292Phe) Homozygous
15 Female c.(?-1)_(*1_?)del p.? (gene deletion) Homozygous
16 Female c.(?-1)_(*1_?)del p.? (gene deletion) Homozygous
17 Male c.1693del/c.968þ 1G>A p.(Glu565Argfs*7)/p.(?) Compound heterozygous
18 Male c.(?-1)_(*1_?)del p.? (gene deletion) Homozygous
19 Male c.(?-1)_(*1_?)del p.? (gene deletion) Homozygous
20 Female c.1987A>T p.(Arg663*) Homozygous
21 Male c.1395delG p.(Tyr465*) Homozygous
22 Male c.(?-1)_(*1_?)del p.? (gene deletion) Homozygous
23 Female c.(?-1)_(*1_?)del p.? (gene deletion) Homozygous
24 Male c.(?-1)_(*1_?)del p.? (gene deletion) Homozygous
25 Male c.182C>A/c.373G>A p.(Ala61Asp)/p.(Glu125Lys) Compound heterozygous
26 Male c.1897delC p.(Leu633*) Homozygous
27 Female c.1929þ 1G>A/c.887G>A p.?/p.(Gly296Asp) Compound heterozygous
28 Male c.182C>A/c.373G>A p.(Ala61Asp)/p.(Glu1125Lys) Compound heterozygous
BSND 29 Female c.452delC p.(Pro151Leufs*27) Homozygous
30 Female c.125G>A/c.139G>A p.(Ser42Asn)/p.(Gly47Arg) Compound heterozygous
SLC12A3 31 Male c.2221G>A/c.3002C>A p.(Gly741Arg)/p.(Ala1001Asp) Compound heterozygous
32 Male c.1202C>A/c.2965 p.(Ala401Asp)/p.(Gly989Arg) Compound heterozygous
33 Male c.2221G>A/c.3052C>T p.(Gly741Arg)/p.(Arg1018*) Compound heterozygous
34 Female c.2878_2879insAGGGGTGCACCCTG p.(Val960Glufs*12) Homozygous
35.1 Female c.626G>A/c.1577A>G p.(Arg209Gln)/p.(Asn526Ser) Homozygous
35.2 Female c.626G>A/c.1577A>G p.(Arg209Gln)/p.(Asn526Ser) Compound heterozygous
36 Male c.647G>A/c.2221G>A p.(Gly216Glu)/p.(Gly741Arg) Compound heterozygous
37 Male c.424G>T/c.2952-?_*1þ?del p.(Val142Leu)/p.?(Exon 26 deletion) Compound heterozygous
38 Female c.2221G>A p.(Gly741Arg) Compound heterozygous
39 Male c.506-1G>A/c.1180þ 1G>T p.?/p.? (splice site) homozygous
Compound heterozygous
Listed are the mutations identified in the 45 patients. Listing of a single variant indicates homozygosity. Reference sequences used for annotation were as follows:
BSND NM_057176.2, CLCNKB NM_000085.3, KCNJ1 NM_000220.2, SLC12A1 NM_000338.2, SLC12A3 NM_000339.2.
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that settled with antacid treatment and switching to ibuprofen
(Patient 20).
Potassium-sparing diuretics
Spironolactone was used in 6/35 BS patients. In one (Patient 24),
it was discontinued at age 15 years due to gynaecomastia and
in a second (Patient 15) it was discontinued due to lack of
biochemical improvement. One patient received amiloride
because of dramatic alkalosis (Patient 29) [10].
Chronic kidney disease
At the last follow-up, 27/45 children (BS 22/35 and GS 5/10) had
an eGFR<90 mL/min/1.73 m2. Pathological albuminuria (urine
Fig. 1. Biochemical data at presentation and last follow-up. Dotted lines indicate upper and lower limits of reference range. (A) Potassium at presentation and (B) at
last follow-up. (C) Bicarbonate at presentation and (D) at last follow-up. (E) Magnesium at presentation and (F) at last follow-up. (G) Urine calcium:creatinine ratio at
presentation. (H) eGFR at last follow-up. *P<0.05. #Bicarbonate as measured in the laboratory (initial bicarbonate calculated on blood gas analysis was 80 mmol/L,
described in detail by Plumb et al. [10]).
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albumin:creatinine ratio >2.5 mg/mmol in boys and >3.5 mg/
mmol in girls) was detected in 31/45 children (BS 28/35 and GS
3/10). There was no statistically significant association of devel-
opment of CKD with either hypokalaemia, nephrocalcinosis or
urinary concentrating ability.
One child (patient 24) with BS Type 3 developed nephrotic-
range proteinuria (3.3 g/day) and underwent a kidney biopsy at
the age of 14 years, when his eGFR was 60 mL/min/1.73 m2, which
demonstrated focal segmental glomerular sclerosis. An angioten-
sin-converting enzyme inhibitor was commenced at low dose
(enalapril 0.06 mg/kg/day), but was temporarily stopped due to an
increase in creatinine by almost 50% (from 123 to 183mmol/L).
When subsequently restarted at half the dose, proteinuria
decreased to 1.8 g/day with stable plasma creatinine (135mmol/L).
One patient with CKD Stage 3 (Patient 33) had been diag-
nosed with vesico-ureteric reflux at 3 years of age after suffering
from recurrent urinary tract infections.
Urinary concentrating ability
Maximal urine osmolalities (Uosm) obtained at clinic visits were
compared according to genotype for those with available data.
The average maximal Uosm in patients with SLC12A1 and
KCNJ1 mutations was 285 6 8 (SEM) mOsm/kg (n ¼ 11), com-
pared with 547 6 17 for CLCNKB (n ¼ 12) and 634 6 65 for
SLC12A3.
In all, six patients (all with antenatal BS) had formal desmo-
pressin (DDAVP) tests because of concerns over the urinary con-
centrating ability. Of these, four patients (1, 2, 8 and 9.1) showed
evidence of secondary nephrogenic diabetes insipidus (sNDI)
with Uosm below plasma osmolality (Posm) after DDAVP. The
two others (Patients 9.2 and 12) showed evidence of
isosthenuria, with Uosm only mildly increasing to 345 and
367 mOsm/kg, respectively, after stimulation with DDAVP.
Extrarenal complications
Intellectual impairment was not systematically evaluated in all
patients but was documented in three patients (2, 10, 11.1) and
was mostly ascribed to complications from prematurity. Patient
10 also has ataxia with cerebellar atrophy, which was deemed
familial, as his sister and aunt (who do not have BS) are also
affected.
Discussion
This study describes the long-term outcome for a large cohort
of patients with BS and GS. Overall, the prognosis appears rea-
sonable, with the most serious complications related to prema-
turity. Genotype–phenotype correlation broadly confirms
results seen in previous cohorts.
Growth
Growth was below average for the cohort, but the mean height
was within two standard deviations. Height SDS improved
slightly with treatment, from 1.6 at presentation to 1.2 at the
last follow-up. GH deficiency has been recurrently reported in
BS [11, 12–15]. In our cohort, three patients were treated with
GH. Of interest is the observation in Patient 23, with BS Type 3,
only showed catch-up growth with concomitant non-steroidal
anti-inflammatory drug (NSAID) treatment. Most reports of GH
deficiency in BS concern patients with CLCNKB mutations, the
type of BS with the most severe biochemical abnormalities. This
raises the question whether GH secretion and response is
impaired by severe hypokalaemia, alkalosis and/or elevated
prostaglandins. Reports of GH deficiency in patients with GS
would argue against an effect of prostaglandins [16, 17]. Yet,
these reported patients had no genetic confirmation of the diag-
nosis, thus it is unclear if they truly had GS or rather BS Type 3.
More systematic investigations are needed to address this
question.
Treatment
Supplementation with sodium and/or potassium was the most
frequently prescribed intervention; this is in keeping with previ-
ously described cohorts [18–20]. Yet, the small differences in
potassium levels between presentation and follow-up (see
Figure 1) demonstrate the difficulties in improving this parame-
ter by supplementation, as an increased blood level results in
an increased filtered load and thus, typically, increased urinary
losses.
In our cohort, treatment with NSAIDs at the last follow-up
was used in more than half of children with BS. Treatment with
NSAIDs was generally well tolerated, although side effects that
prompted temporary or permanent withdrawal were seen in
seven patients. Such withdrawal occurred with indomethacin,
yet this was also the most frequently used NSAID. Thus,
whether complications are more commonly associated with
indomethacin compared with other NSAIDs cannot be answered
from our study. Treatment with so-called cyclooxygenase-2
inhibitors has been suggested for patients with BS, and we
increasingly prescribe it in our current patients, but none of the
patients in this historic cohort received this class of drug [21].
Treatment and tolerance of hypokalaemia is a controversial
topic in hypokalaemic alkalosis, as hypokalaemia can be associ-
ated with complications, yet excessive supplementation can
also be harmful [22]. Interestingly, despite persistent hypokalae-
mia (serum potassium <3.0 mmol/L) in 35/45 patients during
follow-up, only 1 patient experienced overt symptoms, in the
form of hypokalaemic paralysis (serum potassium 1.3 mmol/L);
no arrhythmias were detected with hypokalaemia, but this was
also not routinely screened for.
The classic clinical features of hypovolaemia, hyperaldoster-
onism and the consequent hypokalaemic, hypochloraemic met-
abolic alkalosis can be seen with both renal and extrarenal salt-
wasting states, e.g. chronic and severe gastro-oesophageal
reflux or congenital chloride diarrhoea, and it can be challeng-
ing to distinguish between them. The data presented in this
cohort suggest that FENa cannot reliably distinguish between
renal and extrarenal salt wasting. This is consistent with the
concept that in the long-term salt homeostasis must be in a
steady state, as persistent excess salt excretion would lead to
life-threatening hypovolaemia. In this cohort, all patients with
available data had an FECl >0.5% prior to commencing electro-
lyte supplementation, suggesting that this may be a better indi-
cator for renal salt loss, as FECl in extrarenal salt-losing
conditions is expected to be minimal. Given the importance of
sodium for volume homeostasis, the tubules prioritize sodium
reabsorption above other cations, especially potassium, so that
sodium losses can be minimized. However, both sodium
and potassium need to be accompanied by an anion, typically
chloride and therefore FECl is better suited to detect renal salt
wasting. Obviously these measurements should be obtained
prior to supplementation, or when the patient is clinically hypo-
volaemic. After commencing supplementation, increased renal
excretion may simply reflect the increased intake.
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Chronic kidney disease
Impaired GFR and pathological glomerular proteinuria was seen
in a substantial number of children during follow–up, in keeping
with previous cohorts [19, 20, 23, 24]. In our cohort this was
more common in BS than GS. There are a number of possible
explanations for this. One possibility is that this is secondary to
nephrocalcinosis; however, in the four children with CLCNKB
mutations and CKD, there was no evidence of nephrocalcinosis,
suggesting this is not the cause in these patients. Long-term
treatment with NSAIDs is linked to an increased risk of CKD
[25], however, the doses used in BS and GS are relatively small
(typically 1–2 mg/kg/day of indomethacin) compared with
doses used for analgesia. Moreover, patients with BS have
increased levels of prostaglandins involved in the regulation
of renal perfusion and treatment with NSAIDs does not sup-
press these, but brings them closer to the normal range.
Previous data suggest that the use of NSAIDs in children with
BS is not linked to histological evidence of NSAID-induced
renal damage [18].
A third possibility is chronic hypokalaemia, which in rats
leads to hypertrophy and ultimately renal fibrosis with elevated
transforming growth factor b [26]. Yet, results from adults with
BS and GS suggest that the severity of hypokalaemia is not
directly linked to the degree of CKD [27].
Stimulants of the renin–angiotensin–aldosterone system in
BS and GS include chronic volume depletion, and in BS, ‘short-
circuiting’ of the juxta-glomerular apparatus [6, 10]. There is
experimental and epidemiological work that demonstrates a
damaging effect of elevated aldosterone levels on podocytes,
thus leading to CKD [28, 29]. Potentially this may also contribute
to the CKD seen in children with BS and GS.
Prematurity is an emerging risk factor for CKD [30]. As human
nephrogenesis is not complete until 36 weeks post-gestation,
children born prematurely have an incomplete endowment of
nephrons and therefore undergo ex utero nephrogenesis. In our
cohort, patients with CLCNKB mutations and CKD were born at
term, thus prematurity in these children is unlikely to be the pri-
mary cause of CKD in these patients, but it is a likely contributor
in patients with antenatal BS.
The progression of CKD in BS and GS is likely multifactorial
and therefore patients need regular follow-up to monitor glo-
merular as well as tubular function.
Urinary concentrating ability
We previously reported the presence of an sNDI in two patients
(1 and 2) [31, 32] and confirm this complication in two further
patients with marked polyuria (8 and 9.1). In contrast, the sister
of Patient 9.1 (9.2), as well as Patient 12, showed isosthenuria,
consistent with dysfunction of the loop of Henle [33]. While
sNDI is seen only in patients with antenatal BS, the discrepant
findings in the siblings Patients 9.1 and 9.2 argue against a clear
genotype effect; we also did not note substantial differences in
their plasma electrolytes or urinary calcium concentration.
Clinically these patients pose a management problem: BS is pri-
marily a salt-wasting disorder and consequently supplementa-
tion with salt is a mainstay of treatment. Yet, patients with NDI
need to minimize their salt intake to reduce the osmotic load.
Indeed, the patients with confirmed sNDI all had recurrent
hypernatraemic dehydration (maximal plasma sodium concen-
trations of 165, 161, 148 and 153 mmol/L) and salt supplementa-
tion was either never prescribed or discontinued in these four
patients.
In summary, we report a large cohort of children with BS
and GS with long-term follow-up data treated in a single centre
over a 30-year period. This demonstrates the overall prognosis
in children with BS and GS is reasonable; the majority of chil-
dren reached a height that was within the normal range and
there were very few complications resulting from extreme elec-
trolyte abnormalities. In this cohort, impaired GFR and patho-
logical albuminuria were seen in a large proportion of children,
highlighting the need for follow-up of glomerular as well as tub-
ular function in these patients.
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